From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

US Government Invests in At-Home Single Swab Combined Flu, COVID Test

by Global Biodefense Staff
February 3, 2022
US Government Invests in At-Home Single Swab Combined Flu, COVID Test

Credit: NIAID

Detect Inc.’s over-the-counter home test identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid in less than 30 minutes using a single nasal swab.

Under this contract award from the Biomedical Advanced Research and Development Authority (BARDA), Detect Inc. will advance the development of this next generation device, the Detect COVID/Flu Test, through additional studies required by the U.S. Food and Drug Administration (FDA) to potentially grant Emergency Use Authorization (EUA) and to request 510(k) clearance to market the test kits.

The Detect COVID/Flu Test is intended to be an important home diagnostic tool to aid in pandemic response. The ability for an individual to differentiate between respiratory infections – which often present with similar symptoms – is crucial to guiding personal decisions related to illness and treatment management. This diagnostic test could help increase testing capacity and expand access to testing across the U.S. to more rapidly identify, isolate, and treat individuals with COVID-19 and influenza.

The Detect COVID/Flu Test includes a reusable Detect Hub (Detect’s reusable base station), a single-use cartridge, and an accompanying mobile application. Individuals can perform the test at home without requiring laboratory expertise or sophisticated equipment and receive results in less than 30 minutes.

Detect’s molecular test is designed to rapidly target and amplify nucleic acid sequences through a process known as isothermal amplification. Detect’s isothermal amplification chemistry amplifies nucleic acid sequences directly from patient samples without any pre-processing steps or expensive, complex instrumentation. The molecular test also contains proprietary biochemical reagents that enable SARS-CoV-2 and influenza identification faster than traditional PCR while maintaining accuracy at low viral loads, making it more sensitive than at-home rapid antigen tests. A modular cartridge, designed for multiplexing, will allow users to receive independent test results for influenza A, influenza B, SARS-CoV-2 and potential co-infection while also possessing the capability to quickly reprogram the test to identify new targets and/or pathogenic strains.

If granted EUA, and then subsequent 510(k) clearance by the FDA, the multiplex test could bring COVID-19 and influenza testing to the home setting, thereby providing valuable information to help individuals make more informed care decisions and seek treatment.

From Our Partners
Tags: ASPRAt-Home DiagnosticsAwardsBARDACOVID-19Editor PickHHSInfluenzaRapid Diagnostics

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC